Drug intelligence / Profile preview

insulin lispro protamine + insulin lispro (Eli Lilly and Company)

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Peptides
Administration
Subcutaneous
01

Overview

Insulin lispro 50 mix is a biphasic insulin analog preparation consisting of 50% insulin lispro protamine suspension (an intermediate-acting insulin) and 50% insulin lispro injection (a rapid-acting insulin). This combination is designed to provide both rapid postprandial glucose control and intermediate-acting basal insulin coverage within a single injection. The rapid-acting component, insulin lispro, begins to work quickly after injection to manage blood sugar spikes following meals, while the protamine-bound component provides a more prolonged duration of action to maintain stable glucose levels between meals and overnight. It is primarily indicated for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control. In clinical practice, it is often used in patients who require both prandial and basal insulin but prefer a simplified dosing regimen with fewer daily injections.

Brand names
Humalog Mix 50/50Humalog Mix50
Other names
insulin lispro 50 mixLispro 50Lispro50Lispro-50biphasic insulin lispro 50/50insulin lispro mix 50/50
02

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro protamine + insulin lispro (Eli Lilly and Company).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro protamine + insulin lispro (Eli Lilly and Company).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call